The availability of in vitro prostate cancer models is limited, and the heterogeneous nature of resistance mechanisms to antihormonal therapies in prostate cancer may explain why TLE3 loss did not confer resistance to enzalutamide in LAPC4 and CWR-R1 cells. The gene discussed is TLE3; the disease is prostate cancer.